Your browser is no longer supported. Please, upgrade your browser.
VSTM Verastem, Inc. daily Stock Chart
VSTM [NASD]
Verastem, Inc.
Index- P/E- EPS (ttm)-1.40 Insider Own1.00% Shs Outstand165.40M Perf Week-4.48%
Market Cap215.35M Forward P/E- EPS next Y-0.28 Insider Trans-59.41% Shs Float158.11M Perf Month-7.91%
Income-129.90M PEG- EPS next Q0.04 Inst Own48.70% Short Float6.37% Perf Quarter-13.51%
Sales22.00M P/S9.79 EPS this Y-79.40% Inst Trans0.10% Short Ratio2.65 Perf Half Y-66.40%
Book/sh0.69 P/B1.86 EPS next Y36.40% ROA-69.80% Target Price- Perf Year13.27%
Cash/sh- P/C- EPS next 5Y1.74% ROE-195.30% 52W Range0.83 - 4.67 Perf YTD-4.48%
Dividend- P/FCF- EPS past 5Y0.70% ROI-119.40% 52W High-72.59% Beta0.76
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin92.80% 52W Low54.22% ATR0.08
Employees135 Current Ratio5.00 Sales Q/Q38.70% Oper. Margin- RSI (14)46.01 Volatility4.81% 5.71%
OptionableYes Debt/Eq0.49 EPS Q/Q75.60% Profit Margin- Rel Volume0.31 Prev Close1.31
ShortableYes LT Debt/Eq0.45 EarningsAug 10 BMO Payout- Avg Volume3.81M Price1.28
Recom2.20 SMA20-1.23% SMA50-3.32% SMA200-31.04% Volume1,163,582 Change-2.29%
Jun-20-19Downgrade BTIG Research Buy → Neutral
May-10-19Downgrade Raymond James Outperform → Mkt Perform
Jul-13-18Initiated BTIG Research Buy $17
May-02-18Initiated Seaport Global Securities Buy $14
Mar-08-18Initiated B. Riley FBR, Inc. Buy $15
Sep-07-17Reiterated H.C. Wainwright Buy $6.50 → $10
Apr-13-17Initiated Oppenheimer Outperform
Mar-24-17Reiterated H.C. Wainwright Buy $5 → $6.50
Sep-29-15Downgrade Raymond James Strong Buy → Outperform
Sep-29-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-29-15Downgrade Jefferies Buy → Hold
Sep-29-15Downgrade Cantor Fitzgerald Buy → Hold
Sep-28-15Downgrade ROTH Capital Buy → Neutral $23 → $2
Sep-28-15Downgrade Mizuho Buy → Neutral $21 → $2
Sep-09-15Initiated Raymond James Strong Buy
May-12-15Reiterated UBS Buy $30 → $24
Apr-08-15Initiated H.C. Wainwright Buy $16
Jan-23-15Reiterated ROTH Capital Buy $29 → $23
Jul-08-14Resumed Oppenheimer Perform
Feb-11-14Initiated Mizuho Buy $21
Oct-14-20 10:26AM  
Oct-08-20 08:38AM  
Oct-06-20 07:00AM  
Sep-30-20 08:54AM  
Sep-18-20 11:50AM  
Sep-16-20 07:00AM  
Sep-15-20 08:51AM  
Sep-14-20 07:00AM  
Sep-10-20 04:05PM  
Aug-12-20 09:43AM  
Aug-10-20 04:59PM  
08:33AM  
08:30AM  
Jul-30-20 12:34PM  
Jul-06-20 07:00AM  
Jun-23-20 11:07PM  
Jun-22-20 04:05PM  
May-28-20 07:00AM  
May-19-20 09:47AM  
May-18-20 11:20AM  
May-14-20 09:31AM  
May-07-20 04:05PM  
May-04-20 03:04PM  
May-01-20 11:30AM  
Apr-27-20 12:11AM  
Apr-23-20 08:38AM  
Apr-21-20 05:18PM  
Apr-20-20 07:00AM  
Apr-15-20 09:30AM  
Apr-13-20 06:05PM  
Apr-09-20 07:30AM  
Apr-07-20 04:05PM  
Mar-30-20 10:37AM  
Mar-19-20 11:30AM  
Mar-18-20 07:01AM  
Mar-11-20 04:05PM  
Mar-10-20 09:28AM  
Feb-28-20 06:05AM  
06:00AM  
Feb-05-20 11:52AM  
Jan-29-20 07:06AM  
Jan-21-20 11:14AM  
Jan-09-20 09:00AM  
Jan-08-20 08:12AM  
07:00AM  
Jan-06-20 07:00AM  
Dec-17-19 07:03PM  
Dec-11-19 08:46AM  
Dec-07-19 09:00AM  
Nov-25-19 08:57AM  
07:00AM  
Nov-15-19 11:16PM  
Nov-13-19 07:00AM  
Nov-12-19 08:12AM  
Nov-06-19 09:15AM  
Oct-30-19 07:01AM  
Oct-29-19 07:35PM  
04:17PM  
Oct-23-19 07:00AM  
Oct-17-19 07:00AM  
Oct-09-19 11:18AM  
Oct-08-19 10:02AM  
Oct-07-19 07:00AM  
Oct-04-19 01:41PM  
07:00AM  
Oct-03-19 02:25PM  
07:00AM  
Sep-26-19 07:00AM  
Sep-20-19 01:00PM  
Sep-03-19 04:05PM  
Aug-06-19 08:52PM  
Aug-05-19 01:13PM  
Aug-01-19 07:25PM  
04:05PM  
Jul-30-19 07:00AM  
Jul-29-19 04:05PM  
Jul-26-19 07:26AM  
Jul-25-19 04:05PM  
07:00AM  
Jul-23-19 01:04PM  
Jul-03-19 07:00AM  
Jun-25-19 08:53PM  
Jun-24-19 08:33AM  
Jun-21-19 09:01AM  
07:00AM  
Jun-20-19 09:41AM  
07:00AM  
Jun-19-19 11:20AM  
Jun-17-19 07:00AM  
May-30-19 07:00AM  
May-24-19 02:42PM  
02:35PM  
May-16-19 07:00AM  
May-15-19 05:16PM  
May-13-19 06:44AM  
May-09-19 06:45PM  
05:34PM  
04:05PM  
May-02-19 07:00AM  
Apr-23-19 04:05PM  
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.10% OwnerJun 25Sale1.911,161,3002,219,94116,142,051Jun 29 06:29 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerApr 27Sale2.311,301,3003,002,09917,303,351Apr 29 04:30 PM